The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Larger Will The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Become By 2030 Compared To 2026?

The sodium glucose cotransporter 2 (sglt2) inhibitors market has seen robust expansion over the past few years. It is anticipated to expand from $10.96 billion in 2025 to $11.87 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.3%. The market’s growth during earlier periods is a result of an increase in type 2 diabetes cases, unfulfilled glycemic control requirements, positive clinical trial results, heightened physician awareness, and regulatory endorsements.

The sodium glucose cotransporter 2 (sglt2) inhibitors market is projected to experience substantial expansion in the coming years. This market is forecast to reach $16.35 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.3%. Key factors driving this growth during the forecast period include the increasing recognition of cardio-renal benefits, an expanding aging diabetic population, broader reimbursement coverage, the introduction of new drugs, and greater penetration into emerging markets. Significant trends anticipated over the forecast period encompass their expanded application beyond diabetes treatment, a rise in the adoption of combination therapies, an increase in their use for heart failure indications, enhanced safety profiling, and more extensive inclusion in clinical guidelines.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp

Which Growth Factors Are Strengthening The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Landscape?

A projected expansion of the sodium glucose cotransporter 2 (SGLT2) inhibitor market is anticipated, driven by the rising incidence of diabetes. This condition, diabetes, encompasses various metabolic ailments marked by elevated blood sugar, stemming from impairments in insulin production, its effectiveness, or a combination of both. Contributing factors to the escalation in diabetes diagnoses include urbanization, heightened stress levels, environmental contaminants, and insufficient availability of healthcare provisions. In the management of diabetes, sodium glucose cotransporter 2 (SGLT2) inhibitors function to decrease blood glucose by impeding its reabsorption in the kidneys, thereby facilitating its elimination through urine. These inhibitors additionally provide cardiovascular and renal advantages, positioning them as a significant choice for addressing diabetes and its associated complications. Illustratively, data from March 2025 by the Office for Health Improvement and Disparities (OHID), a UK-Based English government organization, indicated that the prevalence of type 2 diabetes among adults aged 17 and over in England, as documented by GPs, reached 7.0% in March 2024, an increase from 6.8% in March 2023. Consequently, the expanding occurrence of diabetes is propelling the advancement of the sodium glucose cotransporter 2 (SGLT2) inhibitor market.

How Is The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Examined Through Segment Analysis?

The sodium glucose cotransporter 2 (sglt2) inhibitors market covered in this report is segmented –

1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat

2) By Route Of Administration: Oral Route, Other Route Of Administration

3) By End User: Hospitals, Homecare Settings, Clinics

Subsegments:

1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana

2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance

3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga

4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure

What Trends Are Influencing The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Outlook?

Leading companies in the social networking app market are prioritizing the creation of sophisticated, unique content solutions to boost user interaction and distinguish their platforms. An exclusive content solution signifies a particular method or system providing distinctive, owned, or premium material available solely to a select audience or via a specific platform. For example, in February 2024, Dazed Media, a UK-based digital media firm, introduced the Dazed Club app. This dynamic networking platform caters to young creatives, enabling them to upload portfolios, link with mentors, and join specialized groups for project discussions and expert guidance. Users can share their creative output, such as images and videos, and participate in group conversations on various subjects. The app cultivates a lively community and encourages collaboration, granting access to exclusive editorial features from Dazed, event schedules, and chances to take part in contests and product launches.

Who Are The Businesses Driving Activity In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

Major companies operating in the sodium glucose cotransporter 2 (sglt2) inhibitors market are Johnson & Johnson Inc., Merck & Co Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma Inc, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co Ltd, Taisho Pharmaceutical Holdings Co Ltd, Lupin Limited, Glenmark Pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co Ltd, Kotobuki Pharmaceutical Co Ltd, Lexicon Pharmaceuticals Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Hanmi Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, Mitsubishi Tanabe Pharma Corporation

Access The Complete Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report

Which Region Stands As The Largest Contributor To The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (sglt2) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=18473&type=smp

Browse Through More Reports Similar to the Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market 2026, By The Business Research Company

Antidiabetics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Mtor Inhibitors Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/mtor-inhibitors-global-market-report

Kinase Inhibitors Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model